Novo Nordisk AS (OCSE:NOVO B)
kr 757.3 9.7 (1.3%) Market Cap: 3.36 Til Enterprise Value: 3.35 Til PE Ratio: 35.72 PB Ratio: 27.97 GF Score: 97/100

Q3 2023 Novo Nordisk A/S Earnings Call Transcript

Nov 02, 2023 / 12:00PM GMT
Release Date Price: kr709.5 (+3.17%)
Operator

Good day, and thank you for standing by. Welcome to the Q3 2023 Novo Nordisk AS Earnings Conference Call. At this time, all participants are in a listen-only mode aftersales as a question in the session on your telephone. You will then hear an automated message advising your hand is raised. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, Daniel Bohsen, Head of Investor Relations. Please go ahead, sir.

Daniel Bohsen;S;CVP;Head of IR
Novo Nordisk A

/-&

Welcome to this Novo Nordisk Earnings Call for the first 9 months of 2023. This call follows the early announcement of top line results and the updated outlook for 2023 shared in October. The release was advanced due to Danish securities regulations. My name is Daniel Bohsen, and I'm the Head of Investor Relations at Novo Nordisk. With me today, I have CEO of Novo Nordisk, Lars Jorgensen, Executive Vice President and Head of Commercial Strategy and Corporate Affairs, Camilla

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot